References
  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
  2. Mankad AK, Seray I, Shah KB. Light-chain cardiac amyloidosis. Curr Probl Cancer. 2017;41:144-56
  3. Maurer MS, Schwartz JH, Gundapaneni B, Elliot PM et al. Tafamidis treatment for patient with transthyretinin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-16
  4. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, et al. Occult transthyretin cardiac amyloidosis in severe calcific aortic stenosis. Circ Cardiovasc Imaging. 2016;9(8):e005066.
  5. Xu B, Godoy RC, Rodriguez ER, Tan C, et al. Unrecognized cardiac amyloidosis at the time of mitral valve surgery: incidence and outcomes. Cardiology. 2019;1429(4):253-258
  6. Massoudy P, Szabo A, Dirsch O, Wienecke H, van de Wal H, Jakob H. Amyloid of heart and lungs in a patient with low output syndrome after coronary artery bypass grafting. Herz. 2003:28(5):453-6
  7. Fitzmaurice G, Wishart V, Graham A. An unexpected mortality following cardiac surgery: A post-mortem diagnosis of cardiac amyloidosis. Gen Thorac Cardiovasc Surg. 2013;61(7):417-21
  8. Zacek P, Medilek K, Lonsky V, Laco J. Cardiac amyloidosis in the cardiosurgical operating room – a rare but fatal trap. Thorac Cardiovasc surg. 2007;55(2):65-67
  9. Massias S, Vyssoulis G, Rizos I, Barbetseas I, Stefanadis C. Progressive heart failure in a patient after coronary artery bypass grafting. Hell J Cardiol. 2006;47:114-117